News | March 24, 2010

Mayo Clinic Finds Cardiac Rehabilitation Helps Stent Patient Survival


March 24, 2010 – A team of Mayo Clinic researchers found that cardiac rehabilitation is associated with significantly reduced mortality rates for patients who receive coronary stents. The findings were presented last week at the annual meeting of the American College of Cardiology in Atlanta.

Researchers found patients who had coronary angioplasty and afterwards participated in a cardiac rehabilitation program had a 45 to 47 percent decrease in mortality compared to those who did not participate in a cardiac rehabilitation program.

“Patients need to know that once they’ve had a coronary artery stent placed, they are not cured,” says Randal Thomas, M.D., a preventive cardiologist at Mayo Clinic in Rochester, Minn. “Participation in a cardiac rehabilitation program will improve their health outcomes and quality of life.”

The study is one of very few that has looked at mortality rates after coronary angioplasty. “No other studies have been able to include the clinical details we have included,” says Dr. Thomas. The research team examined the records from a special database of 2,351 Mayo Clinic patients who underwent coronary angioplasty between 1994 and 2008. The overall participation rate in cardiac rehabilitation was 40 percent. Individual patients were followed for an average of six years.

In cardiac rehabilitation programs, patients exercise rigorously and get help in controlling risk factors. This leads to health benefits that are evident within the first year, and grow even larger over the long term, Dr. Thomas says.

Although cardiac rehabilitation programs are beneficial, Dr. Thomas says only 20 percent of all eligible cardiac patients nationally and 60 percent of Mayo patients participate. Several factors produce barriers to participation.

“Cardiac rehabilitation wasn’t covered by insurance for patients undergoing angioplasty therapy until 2006,” Dr. Thomas says. “Many patients and providers don’t know that it’s covered now. Also, some patients live far away from a cardiac rehabilitation facility. But what’s most troubling is that physicians often fail to emphasize the need for cardiac rehabilitation with their patients.”

“Cardiac rehabilitation is like a life raft to carry them [heart procedure patients] through the turbulent white water of cardiac trouble,” Dr. Thomas says. “It’s very important that they participate in such a program.”

The study was funded by the Mayo Clinic Division of Cardiology. Co-authors include Kashish Goel, MBBS; Ryan Lennon; R. Thomas Tilbury, M.D.; and Ray Squires, Ph.D., all of Mayo Clinic.

For more information: www.mayo.edu


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now